GLP-1 Agents May Reduce Psoriasis Severity - Takeaways - MDSpire

GLP-1 Agents May Reduce Psoriasis Severity

National Psoriasis Foundation review highlights limited evidence and potential metabolic links.

  • By

  • Andrea Surnit

  • May 5, 2026

  • 4 min

Share

  • 1

    GLP-1 receptor agonists may reduce psoriasis severity in patients with metabolic comorbidities, but evidence is limited and inconsistent.

  • 2

    Small trials indicated 40% to 80% reductions in PASI scores, especially in patients with obesity or type 2 diabetes.

  • 3

    Liraglutide and semaglutide showed significant PASI score reductions in open-label trials, but findings varied across studies.

  • 4

    GLP-1 RAs can be coadministered with other psoriasis treatments and primarily cause gastrointestinal adverse effects.

  • 5

    Current evidence is limited by small sample sizes and short follow-up, with GLP-1 RAs not approved for psoriasis treatment.

Original Source(s)

GLP-1 Agents May Reduce Psoriasis Severity

  • by Andrea Surnit

  • May 5, 2026

Related Content

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

Investigating the Therapeutic Mechanisms and Key Bioactive Compounds of Solanum nigrum in Treating Psoriatic Lesions

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial